Phase II study of bevacizumab combined with oral leucovorin plus UFT for elderly patients with metastatic colorectal cancer. - Phase II study of bevacizumab combined with oral leucovorin plus UFT for elderly patients with metastatic colorectal cancer.

Tukuba cancer clinical trial group Shikoku gastrointestinal oncology study group0 个研究点目标入组 55 人开始时间: 2010年4月26日最近更新: 2023年10月17日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 55

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Of the 55 patients enrolled. Their median age was 80 years (range, 75-87 years) The median PFS was 8.2 months (95% confidence interval [CI], 6.2-10 months). UFT/LV (3 weeks of therapy and 1 week without) combined with biweekly bevacizumab is a tolerable and effective treatment option for elderly patients (aged over 75 years) with metastatic colorectal cancer.

研究设计

研究类型: Interventional

入排标准

年龄范围: 75years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•1)Concurrent treatment with prohibited medications, including phenytoin 2)Administration contraindication of UFT, leucovorin and bevacizumab 3)Serious infection 4)HBsAg potitive 5)Active double cancer 6)Uncontrolled hypertention 7)Severe complications 8)Massive pleural or abdominal effusion 9)Patient with the diarrhea 10)Brain metastasis 11)Uric protein 2+ 12)Men of the fertility hope 13)Pregnant or lactating female at any time during study 14)Systemic administration of corticosteroids 15)Thrombosis , cerebral infraction , cardiac infraction , pulmonary infraction 16)Patients who underwent surgery within 4 weeks 17)Systemic administration of antiplatelet drug 18)Patients with known bleeding disorders or clotting disorder 19)Severe mental illness 20)Patients who are judged inappropriate for the entry into the study by the investigator

研究者

发起方

Tukuba cancer clinical trial group Shikoku gastrointestinal oncology study group

相似试验

终止

1 期

Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung CancerNon-Small Cell Lung Cancer

NCT00351039H. Lee Moffitt Cancer Center and Research Institute8

进行中（未招募）

1 期

A clinical trial to investigate efficacy and safety of continous treatment with bevacizumab together with chemotherapy in elderly patients with metastasized colorectal cancerMetastatic colorectal cancer

EUCTR2014-003844-11-SEDepartment of Oncology, Linköping University Hospital, Linköping, Sweden48

进行中（未招募）

不适用

Phase II clinical study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic breast cancerMetastatic or locally recurrent HER2-negative breast cancerMedDRA version: 12.0Level: LLTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 12.0Level: LLTClassification code 10006198Term: Breast cancer recurrent

EUCTR2009-016062-82-HUSOUTH EASTERN EUROPEAN RESEARCH ONCOLOGY GROUP88

进行中（未招募）

不适用

Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal Cancer

EUCTR2005-001012-41-ITROCHE

进行中（未招募）

不适用

Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.MedDRA version: 14.1Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2005-000802-30-ITROCHE